Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function.

[1]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[2]  L. Fisher,et al.  Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT) , 2003, Circulation.

[3]  C. Zanker,et al.  Comparative value of Doppler echocardiography and B-type natriuretic peptide assay in the etiologic diagnosis of acute dyspnea. , 2002, Journal of the American College of Cardiology.

[4]  M. Enriquez-Sarano,et al.  Quantitation of mitral regurgitation: rationale, approach, and interpretation in clinical practice , 2002, Heart.

[5]  G. Habib,et al.  Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. , 2002, Circulation.

[6]  Douglas W Mahoney,et al.  Plasma brain natriuretic peptide concentration: impact of age and gender. , 2002, Journal of the American College of Cardiology.

[7]  Alan S Maisel,et al.  Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. , 2002, The New England journal of medicine.

[8]  M. Redfield,et al.  The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. , 2002, Journal of cardiac failure.

[9]  A. DeMaria,et al.  Utility of B-Natriuretic Peptide in Detecting Diastolic Dysfunction: Comparison With Doppler Velocity Recordings , 2002, Circulation.

[10]  E. Antman,et al.  ACC/AHA PRACTICE GUIDELINES ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary , 2002 .

[11]  M. Vogeser,et al.  Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. , 2001, Journal of the American College of Cardiology.

[12]  K. Swedberg,et al.  Guidelines for the diagnosis and treatment of chronic heart failure. , 2001, European heart journal.

[13]  L. Lenert,et al.  A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. , 2001, Journal of the American College of Cardiology.

[14]  L. Tavazzi,et al.  Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. , 2001, Journal of the American College of Cardiology.

[15]  V. Cameron,et al.  Atrial (ANP) and brain natriuretic peptide (BNP) expression after myocardial infarction in sheep: ANP is synthesized by fibroblasts infiltrating the infarct. , 2000, Endocrinology.

[16]  M. Kinoshita,et al.  High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. , 2000, Journal of the American College of Cardiology.

[17]  C. Frampton,et al.  Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.

[18]  W. Klein,et al.  Natriuretic peptides in patients with diastolic dysfunction due to idiopathic dilated cardiomyopathy. , 1999, European heart journal.

[19]  M. Simoons,et al.  Relation of atrial natriuretic peptides to left ventricular systolic and diastolic function in heart failure , 1999, European journal of heart failure.

[20]  F. Amiri,et al.  Regulation of natriuretic peptide secretion by the heart. , 1999, Annual review of physiology.

[21]  W. Shimizu,et al.  Diagnostic value of plasma levels of brain natriuretic peptide in arrhythmogenic right ventricular dysplasia. , 1998, Circulation.

[22]  Mario J. Garcia,et al.  New Doppler echocardiographic applications for the study of diastolic function. , 1998, Journal of the American College of Cardiology.

[23]  C. Frampton,et al.  Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. , 1998, Circulation.

[24]  H. Tunstall-Pedoe,et al.  Biochemical detection of left-ventricular systolic dysfunction , 1998, The Lancet.

[25]  G. Lamas,et al.  Clinical significance of mitral regurgitation after acute myocardial infarction. Survival and Ventricular Enlargement Investigators. , 1997, Circulation.

[26]  L. Tavazzi,et al.  Loading manipulations improve the prognostic value of Doppler evaluation of mitral flow in patients with chronic heart failure. , 1997, Circulation.

[27]  Mario J. Garcia,et al.  An index of early left ventricular filling that combined with pulsed Doppler peak E velocity may estimate capillary wedge pressure. , 1997, Journal of the American College of Cardiology.

[28]  J. Gorcsan,et al.  Right ventricular performance and contractile reserve in patients with severe heart failure. Assessment by pressure-area relations and association with outcome. , 1996, Circulation.

[29]  J. Sanderson,et al.  Diastolic dysfunction and natriuretic peptides in systolic heart failure. Higher ANP and BNP levels are associated with the restrictive filling pattern. , 1996, European heart journal.

[30]  A. Richards,et al.  Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. , 1993, The Journal of clinical endocrinology and metabolism.

[31]  N Reichek,et al.  Echocardiographic Determination of Left Ventricular Mass in Man: Anatomic Validation of the Method , 1977, Circulation.